(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)



Fig. 1. Targeted deletion of the AF-1-containing A/B region of RXR{alpha}. (a) Representation of the wild-type RXR{alpha}1 isoform (WT RXR{alpha}1) and the mutant RXR{alpha} (RXR{alpha}{Delta}A/B). Exons E1 to E3 are shown. The functional domains are depicted as followed: AF-1, activation function 1; AF-2 AD, activation function 2 activating domain; DBD, DNA-binding domain (region C); LBD, ligand-binding domain (region E). The RXR{alpha}af1 mutation leads to the production of an RXR{alpha} protein truncated from amino acid 11 to 132. BglII(Bg) and NheI(N) restriction sites were introduced to allow detection of the mutant allele. E{Delta}[2-3] contains the first codon of exon 2 fused to the 3' part of exon 3. The deletion is represented by a black box. (b) The WT RXR{alpha} locus, the targeting construct and the mutated loci obtained after replacement (I), and subsequent Cre-mediated excision of the ‘floxed’ TK-NEO cassette (II). The star represents the mutation E{Delta}[2-3] described in (a). LoxP sites are represented by black arrowheads. Probes A, B and C are 0.7 kb ScaI-SpeI, 0.6 kb EcoRI-BglII and 0.3 kb BamHI-SpeI fragments, respectively. The size of the restriction fragment that allow identification of WT and targeted alleles (I) and (II) by Southern blot analysis using probes A, B, C and neo are indicated below (in kilobases). N, NheI; Bg, BglII; Sc, ScaI; S, SpeI; E, EcoRI; H, HindIII; B, BamHI; X, XbaI; Xh, XhoI. (c) Southern blotting of ES cell DNA digested with BglII or SpeI and hybridized with probe A, B and neo, as indicated. WT (+/+) and RXR{alpha}af1 mutant alleles before (+/(I)) or after (af1/+) excision of the ‘floxed’ TK-NEO cassette are indicated. (d) Detection of RXR{alpha}{Delta}A/B protein. Nuclear extracts prepared from 12.5-day-old embryos WT (+/+), af1 heterozygote (af1/+), af1 homozygote (af1o) and RXR{alpha}-null mutants (-/-) (Kastner et al., 1994) were analyzed by western blotting with the anti-RXR{alpha} monoclonal antibody 4RX3A2, directed against a C-terminal epitope.